相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon
Sanna Rosengren et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2012)
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Roy Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2012)
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
Naresh Punwani et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
New biologic drugs get under the skin of psoriasis
Sarah C. P. Williams
NATURE MEDICINE (2012)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Canadian Guidelines for the Management of Plaque Psoriasis: Overview
Kim Papp et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2011)
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi et al.
JOURNAL OF IMMUNOLOGY (2011)
Signal transduction pathways and transcriptional regulation in Th17 cell differentiation
Kiyoshi Hirahara et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
Treatment of plaque psoriasis with the two-compound product calcipotriol/betamethasone dipropionate versus both monotherapies: An immunohistochemical study
Haike M. J. van der Velden et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2010)
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
Debra M. Meyer et al.
JOURNAL OF INFLAMMATION-LONDON (2010)
Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy
Emoke Racz et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2009)
Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
Mary G. Boy et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Progress in Understanding the Immunopathogenesis of Psoriasis
R. K. H. Mak et al.
ACTAS DERMO-SIFILIOGRAFICAS (2009)
An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 μg/g ointment vs. calcipotriol 50 μg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis
X. Zhu et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2007)
Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease
Lynda A. O'Sullivan et al.
MOLECULAR IMMUNOLOGY (2007)
The JAK-STAT signaling pathway: Input and output intergration
Peter J. Murray
JOURNAL OF IMMUNOLOGY (2007)
分享论文
